Literature DB >> 11247889

Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease.

P J Roberts1, K Morgan, R Miller, J O Hunter, S J Middleton.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is associated with changes in colonic motility which may contribute to the pain and diarrhoea associated with exacerbations of this disease. These changes may be mediated by prostaglandins which are increased in this condition. Increased expression of the inducible isoform of cyclo-oxygenase (COX-2) has been found in active IBD although its cellular distribution remains uncertain. AIMS: To evaluate the cellular distribution of COX-2 in active IBD. PATIENTS AND METHODS: Using reverse transcription-polymerase chain reaction, in situ hybridisation, and immunohistochemistry, COX-2 expression was evaluated in 12 colectomy specimens from patients with active ulcerative colitis (UC), and six specimens from patients with Crohn's colitis that had failed medical therapy. Histologically normal colon was obtained from 12 patients having resection for colorectal neoplasia and evaluated as above, acting as control specimens.
RESULTS: All specimens expressed COX-2 mRNA, with some 6-8-fold increase in inflamed tissues on densitometric analysis (both UC and Crohn's) compared with controls. In situ hybridisation localised this mRNA to myenteric neural cells, surrounding smooth muscle cells, and inflammatory cells of the lamina propria in the IBD specimens, with some weaker labelling seen in the epithelium. No COX-2 labelling was seen in normal tissues. Immunohistochemistry confirmed these sites of COX-2 expression in all inflamed specimens, with absence of immunoreactivity in control tissues.
CONCLUSIONS: These findings provide the first evidence of COX-2 expression in neural cells of the myenteric plexus in active IBD which, via increased prostaglandin synthesis at this site, may contribute to the dysmotilty seen in this condition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11247889      PMCID: PMC1728255          DOI: 10.1136/gut.48.4.468

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Defect in colonic smooth muscle contraction in patients with ulcerative colitis.

Authors:  W J Snape; R Williams; P E Hyman
Journal:  Am J Physiol       Date:  1991-12

2.  Mechanical stretch/relaxation of cultured rat mesangial cells induces protooncogenes and cyclooxygenase.

Authors:  Y Akai; T Homma; K D Burns; T Yasuda; K F Badr; R C Harris
Journal:  Am J Physiol       Date:  1994-08

3.  Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum.

Authors:  R A Lawrence; R L Jones; N H Wilson
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

4.  Stimulatory (EP1 and EP3) and inhibitory (EP2) prostaglandin E2 receptors in isolated ileal smooth muscle cells.

Authors:  A Botella; M Delvaux; J Fioramonti; J Frexinos; L Bueno
Journal:  Eur J Pharmacol       Date:  1993-06-11       Impact factor: 4.432

5.  Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon.

Authors:  M Mourelle; F Casellas; F Guarner; A Salas; V Riveros-Moreno; S Moncada; J R Malagelada
Journal:  Gastroenterology       Date:  1995-11       Impact factor: 22.682

6.  On the specificity of altered muscle function in experimental colitis in rats.

Authors:  L Grossi; K McHugh; S M Collins
Journal:  Gastroenterology       Date:  1993-04       Impact factor: 22.682

7.  Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease.

Authors:  I I Singer; D W Kawka; S Scott; J R Weidner; R A Mumford; T E Riehl; W F Stenson
Journal:  Gastroenterology       Date:  1996-10       Impact factor: 22.682

8.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Authors:  J L Masferrer; B S Zweifel; P T Manning; S D Hauser; K M Leahy; W G Smith; P C Isakson; K Seibert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  Prostaglandin E2 modulates neurally induced nonadrenergic, noncholinergic gastric relaxations in the rabbit in vivo.

Authors:  M C Baccari; F Calamai; G Staderini
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

10.  Involvement of eicosanoids and macrophage-like cells in cytokine-mediated changes in rat myenteric nerves.

Authors:  A Rühl; I Berezin; S M Collins
Journal:  Gastroenterology       Date:  1995-12       Impact factor: 22.682

View more
  21 in total

1.  Inverse expression of prostaglandin E2-related enzymes highlights differences between diverticulitis and inflammatory bowel disease.

Authors:  Liying Dai; Denis W King; D Shevy Perera; David Z Lubowski; Elizabeth Burcher; Lu Liu
Journal:  Dig Dis Sci       Date:  2015-02-11       Impact factor: 3.199

2.  Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs.

Authors:  Angela M Meyer; Nizar N Ramzan; Russell I Heigh; Jonathan A Leighton
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

3.  Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in mice.

Authors:  Jaspreet Kalra; Madhu Cholenahalli Lingaraju; Karikalan Mathesh; Dhirendra Kumar; Subhashree Parida; Thakur Uttam Singh; Anil Kumar Sharma; Dinesh Kumar; Surendra Kumar Tandan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-12-26       Impact factor: 3.000

4.  Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice.

Authors:  M Fornai; C Blandizzi; R Colucci; L Antonioli; N Bernardini; C Segnani; B Baragatti; S Barogi; P Berti; R Spisni; M Del Tacca
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

5.  CUEDC2 Protects Against Experimental Colitis and Suppresses Excessive Proliferation of Intestinal Mucosa.

Authors:  Shaoxin Wang; Jiang Pu; Na Li; Chuanfeng Li; Chao Li; Lan Yu; Xiaohui Wang; Shanfeng Fu; Lihong Cui
Journal:  Dig Dis Sci       Date:  2015-07-17       Impact factor: 3.199

6.  Pain management in patients with inflammatory bowel disease: insights for the clinician.

Authors:  Arvind Iyengar Srinath; Chelsea Walter; Melissa C Newara; Eva M Szigethy
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

7.  Mechanisms involved in the loss of excitatory post-stimulus responses by inflammation.

Authors:  Inge Depoortere; Theo Thijs; Leen Thielemans; Theo L Peeters
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-19       Impact factor: 3.000

8.  The functional -765G→C polymorphism of the COX-2 gene may reduce the risk of developing crohn's disease.

Authors:  Hilbert S de Vries; Rene H M te Morsche; Martijn G H van Oijen; Iris D Nagtegaal; Wilbert H M Peters; Dirk J de Jong
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

Review 9.  Neuroanatomy of lower gastrointestinal pain disorders.

Authors:  Wim Vermeulen; Joris G De Man; Paul A Pelckmans; Benedicte Y De Winter
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

10.  The GPR55 antagonist CID16020046 protects against intestinal inflammation.

Authors:  A Stančić; K Jandl; C Hasenöhrl; F Reichmann; G Marsche; R Schuligoi; A Heinemann; M Storr; R Schicho
Journal:  Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.